Scientific program

Program Tuesday, November 24, 2026

9:00 am

Check-in

10:00 am

Welcome

10:15 am

Session I

Chairs: Ulrike Köhl (Fraunhofer IZI / University Medicine Leipzig, Germany) & Florian Lordick (University Medicine Leipzig, Germany)

Navigating the bridge from lab to clinic in stem cell-based therapies

Keynote

Thomas Hassing Ronøe Carlsen (Novo Nordisk Foundation Cellerator, Denmark)

Optimising efficacy of tumor-specific T cells and manufacturing scalability

Keynote

Felix Lorenz (Captain T Cell, Germany)

Engineering persistence in off-the-shelf cell therapies

Keynote

Karl-Johan Malmberg (University of Oslo, Norway)

11:45 am

Break

12:00 pm

Industry symposium

Supported by AstraZeneca GmbH

Logo AstraZeneca

The evolving CAR-T landscape in multiple myeloma: Advances in design, targeting, and manufacturing
Johannes Waldschmidt (Charité – Universitätsmedizin Berlin, Germany)
Michael Hudecek (University Hospital Würzburg, Germany)

12:45 pm

Break

1:30 pm

Industry symposium – Immune modulating therapies in oncology: From bench to bedside

Supported by J&J Innovative Medicine Janssen-Cilag GmbH

Logo Johnson&Johnson

Chair: Stephan Fricke (Fraunhofer IZI / University Medicine Magdeburg, Germany)

Next steps of cell- and antibody-based therapy from an industry perspective: Advances in (immune) oncology of Johnson & Johnson
Ralf Angermund (J&J Innovative Medicine, Germany)

CAR-T cell therapy – Translating science into clinical practice
Vladan Vucinic (University Medicine Leipzig, Germany)

Discussion and future perspectives
Stephan Fricke (Fraunhofer IZI / University Medicine Magdeburg, Germany)

2:15 pm

Break

2:30 pm

Session II

Chairs: Zoltan Ivics (Fraunhofer IZI, Germany) & Claire Fabian (Fraunhofer IZI, Germany)

Reprogramming the tumor microenvironment toward immune activation by targeted gene-based cytokine delivery

Keynote

Luigi Naldini (Vita-Salute San Raffaele University, Italy)

Fantastic parvoviral gene therapy vectors and how to find them

Keynote

Dirk Grimm (University of Heidelberg, Germany)

Flash Talk

Minicircle DNA for virus-free engineering of gene-modified cells

Marcello Stein (PlasmidFactory GmbH, Germany)

Supported by PlasmidFactory GmbH

Logo Plasmid Factory

Inducing immunogenic lymphoid niches across cancers by tumor-to-dendritic cell reprogramming
Gaia Fontanari (Lund University, Sweden)

4:00 pm

Poster session I

PP01 – Endoplasmic reticulum stress modulation reshapes the tumor immune microenvironment and enhances dendritic cell vaccine efficacy in ovarian cancer
Barbora Vavrušáková (Czech Republic)

PP03 – Advancements in automated TIL manufacturing: Clinical-scale pre-REP and REP using CliniMACS Prodigy®
Julia Atanasov (Germany)

PP05 – Morphomechanical phenotyping of human immune cells by high-throughput deformability cytometry (DC)
Jessica Freitag (Germany)

PP07 – Assessing TCR T cell therapies for solid tumors using 3D bioprints
Xu Holtkotte (Germany)

PP09 – Evolution of CD4‑specific CAR constructs towards clinical application in NK cell therapies
Leonhard Schlosser (Germany)

PP11 – Identification of vector integration sites in Cilta-Cel-treated multiple myeloma patients
Conny Blumert (Germany)

PP13 – Multimodal profiling reveals actionable vulnerabilities in CAR T-derived T-cell lymphoma
Christina Kuhn (Germany)

PP15 – BioThrust bioreactor technology for scalable production of allogeneic NK cell therapeutics
Kristina Roth (Germany)

PP17 – Exploring low-energy electron irradiation as an alternative to extracorporeal photopheresis for GvHD treatment
Maria Schricker (Germany)

PP19 – CD19- and CD20-directed NKG2D bispecific antibodies to restore the NKG2D axis and to potently activate NK cells against leukemia cells
Katja Klausz (Germany)

PP21 – Increasing filling precision: Advances in the CliniMACS Prodigy® TCTf process
Bianca Weidemann (Germany)

PP25 – Next-generation CLEC12A-CAR-NK cells combining a novel VHH binding domain and KLRC1 disruption for AML immunotherapy
Janika Sosat (Germany)

PP27 – T2EVOLVE Association: A sustainable European ecosystem for innovation and access in cell-based therapies
Carmen Sanges (Germany)

PP29 – A single-cell, droplet-based assay for CAR-T potency profiling: Effector and target cell viability and cell-cell contact kinetics on the Envisia platform
Clare Szybut (UK)

PP31 – Microbial metabolite-guided CAR T-cell engineering enhances anti-tumor immunity
Maik Luu (Germany)

PP33 – Targeting the molecular mimicry induced by sialyl transferase-expressing C. jejuni strains during Guillain-Barré syndrome by tailor-made cellular immunotherapies
Sandra Freier (Germany)

PP35 – Scalable hollow-fiber impeller bioreactor for primary T cell expansion: Evaluation of fed-batch and perfusion modes
Felipe Veliz Valenzuela (Germany)

PP37 – Towards a universal lipid nanoparticle (LNP) platform for multiplex engineering of next- generation ex vivo cell therapies
Martin Rabel (Canada)

PP39 – Synthetic Transposons for Individualised Cell and Gene Therapies
Chris Lamprecht (Germany)

PP41 – Development of a TCR-like CAR with enhanced antigen sensitivity to improve CAR T cell therapy against solid tumors
Juliane Kliehm (Germany)

PP45 – Scalable iPSC manufacturing and differentiation using innovative membrane-stirrer bioreactors: from high-density expansion to functional cell therapies
Marco Oliveira (Germany)

PP47 – EGFR-targeting CAR-NK92 cells engage prostate cancer spheroids
Mina Abroudi (Finland)

PP49 – Modulation of CAR T cell immunoreactivity using MAX.16H5 antibody incubation for the generation of immunotolerant allogeneic CAR T cells
Nadine Heimer (Germany)

PP51 – Mechanistic modeling of anti-BCMA CAR-T cell dynamics in relapsed and refractory multiple myeloma
Yuri Garcia Vilela (Germany)

5:00 pm

Session III

Chairs: Stephan Fricke (Fraunhofer IZI / University Medicine Magdeburg, Germany) & Sandy Tretbar (Fraunhofer IZI, Germany)

From science to scale: Lessons in cell therapy development

Keynote

Angela Vollstedt (Novartis, Austria)

The evolving field of cellular therapy in LBCL

Keynote

Anna Sureda (Catalan Institute of Oncology, Spain)

Longitudinal tracing of long-term persisting CAR T cells following ciltacabtagene autoleucel treatment in patients with multiple myeloma
Michael Rade (Fraunhofer IZI, Germany)

Development of novel CAR cell therapeutics in pediatric AML
Sabrina Schuster (Goethe-University Frankfurt, Germany)

6:30 pm

Get-together

Program Wednesday, November 25, 2026

8:15 pm

Check-in

9:00 am

Session IV

Chair: Dominik Schmiedel (Fraunhofer IZI, Germany) & Katharina Schindler-Wnek (Fraunhofer IZI, Germany)

Fraunhofer IZI – Accelerating innovation in cell and gene therapy: Research-driven solutions from process development to manufacturing
Anna Dünkel (Fraunhofer IZI, Germany)

Flash Talk

Understanding the barriers of CAR-T therapy and development towards point-of-care operational models

Dominik Griebling (Fresenius, Germany)

Supported by Fresenius SE & Co. KGaA

Logo Fresenius Kabi

Clinical and manufacturing advances in allogeneic NK and CAR-NK cell therapy: From MRD-positive AML to autoimmune disease
Jan Spanholtz (Glycostem Therapeutics, The Netherlands)

9:45 am

Break

10:00 am

Session V

Chairs: Florian Lordick (University Medicine Leipzig, Germany) & Ulrich Hacker (University Medicine Leipzig, Germany)

Role of microbiome for response to chemotherapy and immunotherapy in gastrointestinal cancers

Keynote

Joseph Tintelnot (Universitätsklinikum Hamburg-Eppendorf, Germany)

Due to a short-term change, this presentation will be given by Irena Beidler (Universitätsklinikum Hamburg-Eppendorf, Germany).

Decoding MSI cancers: From the immune microenvironment to response and resistance to immunotherapy

Keynote

Florence Renaud (Sorbonne University, France)

Loss of LEDGF/p75 disrupts DNA damage signaling and sensitizes patient-derived colorectal cancer cells to 5-fluorouracil
Victoria Liedtke (Brandenburg University of Technology Cottbus-Senftenberg, Germany)

Functional MMR empowers efficient cDC1 reprogramming in MSS colorectal cancer
Sandra Schwarz (University Medical Center Rostock, Germany)

11:30 am

Break

11:45 am

Industry symposium – Advancing hematology: Current therapies in MDS and the future in multiple myeloma

Supported by Bristol Myers Squibb GmbH & Co. KGaA

Logo Bristol Myers Squibb

Chair: Stephan Fricke (Fraunhofer IZI / University Medicine Magdeburg, Germany)

Treatment update in lower-risk MDS
Kathrin Rieger (Charité – Universitätsmedizin Berlin, Germany)

CELMoDs in multiple myeloma – Mezigdomide data deep dive
David Böckle (Charité – Universitätsmedizin Berlin, Germany)

12:30 pm

Break

1:15 pm

Poster session II

PP02 – Development of CAR NK cell therapy inspired by mechanistic study of immune evasion in solid tumors
Manasa Srinivasan (India)

PP04 – Leaving SB100X behind – Development of a new hyperactive Sleeping Beauty transposase for cell engineering
Natalie Forkert (Germany)

PP06 – Investigating small molecule modulators of temozolomide and thymidine toxicity in glioblastoma multiforme
Manasvini Sridharr (Germany)

PP08 – Volatilomic and biomechanical analysis as windows into immune cell function
Emilia Flores Naranjo (Germany)

PP10 – CAR FINDER: Revolutionizing CAR T cells
Robert Serfling (Germany)

PP12 – Establishment of a cell line based antibodydependent cellular phagocytosis (ADCP) assay, using frozen assay ready cells
Felix Hackstein (Germany)

PP14 – Bridging the gap: Developing bispecific antibodies as adaptor molecules for LNP-mediated in vivo CAR T cell engineering in AML
Ela Çetin (Germany)

PP16 – Humanized mouse models for the preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers – Enhanced in vivo and ex vivo analysis enables deeper characterization
Maria Stecklum (Germany)

PP18 – Targeting B cell neoplasia with NKp30-directed bispecific natural killer cell engagers
Dorothee Winterberg (Germany)

PP20 – Lipid nanoparticle-mediated mRNA delivery for ex vivo engineering of CD123-specific CAR NK cells
Nadine von Auw (Germany)

PP22 – Development of a cost-effective allogenic macrophage cell therapy against solid tumors
Jessica Nitsche (Germany)

PP24 – Dual nanobody-CAR-NK cells facilitate versatile „OR-Gated“ killing to mitigate antigen escape in AML
Kamala Bharathi Ramalingam (Germany)

PP26 – Spatial biodistribution analysis of in vivo generated CAR T cells using MICS technology
Juliane Schwarzer (Germany)

PP28 – Establishment of an in vitro epithelial-endothelial co-culture barrier model to investigate CAR-T-cell-interactions with physiological barriers
Charlotte Schwister (Germany)

PP30 – LipiGo enables extrahepatic RNA delivery as a foundation for in vivo immune-cell engineering
Ceren Kimna (Germany)

PP32 – Operational barriers drive access limitations to CAR-T cell therapy in Germany: Results from the EASYGEN multicenter survey
Dominik Griebling (Germany)

PP34 – The transmembrane adaptors SIT and TRIM as tunable negative regulators of T cell activation and checkpoint balance
Nouria Jantz-Naeem (Germany)

PP36 – Metformin alleviates CD8+ T cell exhaustion induced by cancer-conditioned adipose-derived mesenchymal stromal cells in association with reduced mitochondrial hyperpolarization
Chau Ton Nu (South Korea)

PP38 – Epstein–Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways
Alina Steffens (Germany)

PP40 – Proximity network assay (PNA) technology, decodes the membrane architecture of CAR T cells during tumor interaction
Hanna van Ooijen (Sweden)

PP42 – Tyrosine kinase inhibitors as sensitisers for CAR T-cell therapy in solid tumour
Dmitry Chernyakov (Germany)

PP44 – Reducing barriers to pediatric CAR-T therapy: A simplified and efficient anti-CD19 CAR-T cell production using the G-Rex system
Aesha Ali (Qatar)

PP46 – VivoCell: An open-access precision delivery platform for in vivo CAR T cell engineering
Devin Stranford (USA)

PP48 – Systematic cytokine screen identifies dual IL-2/IL-21 armoring as a potent NK cell strategy against high-risk AML
Sebastian John (Germany)

PP50 – A novel cell surface protein interactome approach to immune synapse reorganization after bispecific antibody therapy
Christina Kuhn (Germany)

PP52 – mRNA-delivered mutant IL-2 preferentially expands mutant IL-2Rα-engineered T cells for enhanced solid-tumor control
Matthias Birtel (Germany)

2:15 pm

Session VI

Chairs: Ulrike Köhl (Fraunhofer IZI / University Medicine Leipzig, Germany) & Katrin Mestermann (Fraunhofer IZI, Germany)

In vivo CAR T cells have reached the clinical stage

Keynote

Christian Buchholz (Paul-Ehrlich-Institut, Germany)

CAST: A translational platform to facilitate cell and gene therapy

Keynote

Mattias Carlsten (Karolinska Institutet, Sweden)

Keynote

Knut Steffensen (Karolinska Institutet, Sweden)

Allogeneic TCR-engineered NK cells as an off-the-shelf platform for intracellular antigen targeting in infection and cancer
Frederik Feigl (Fraunhofer IZI, Germany)

A next-generation ionizable lipid LNP platform for efficient in vivo CAR T cell generation across species through passive and active immune cell targeting strategies
Martin Rabel (Cytiva, Canada)

Archive

Scientific program 2024

Scientific program 2023

Scientific program 2022

Scientific program 2021